SLP
Get informed when a big investor buys or sells
+ FollowUndervalued by 26.7% based on the discounted cash flow analysis.
| Market cap | $371.93 Million |
|---|---|
| Enterprise Value | $342.64 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.22 |
| Beta | 1.33 |
| Outstanding Shares | 20,170,000 |
| P/E Ratio | 44.88 |
|---|---|
| PEG | -42.61 |
| Price to Sales | 4.61 |
| Price to Book Ratio | 3.07 |
| Enterprise Value to Revenue | 4.18 |
| Enterprise Value to EBIT | -5.3 |
| Enterprise Value to Net Income | 42 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.04 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 6.60% |
|---|---|
| Total Calls | 14,400▼ 92.80% |
| Total Puts | -▼ 100.00% |
Holdings and activity of institutional investors.
| Ownership % | 79.57%▼ 0.51% |
|---|---|
| Total Invested | $292.56M▲ 53.08% |
| Investors Holding | 170▲ 9.00% |
No data
Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With its subsidiaries, Cognigen, DILIsym Services, and...